Literature DB >> 15821841

Successful treatment of hypotension associated with stunned myocardium with oral midodrine therapy.

Sanjiv Sharma1, Brijesh Bhambi.   

Abstract

Myocardial stunning, a reversible decrease in the contractile function of the myocardium after an ischemic insult, often leads to hypotension that requires therapy with intravenous inotropes. We used the oral agent midodrine to treat hypotension that complicated myocardial stunning after successful revascularization with percutaneous coronary intervention in the setting of myocardial infarction and ischemia. Oral midodrine may offer a useful substitute to intravenous inotropic therapy and can shorten the duration of intensive care unit and hospital stay in this setting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15821841     DOI: 10.1177/107424840501000109

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  4 in total

Review 1.  Cardiac α1A-adrenergic receptors: emerging protective roles in cardiovascular diseases.

Authors:  Jiandong Zhang; Paul C Simpson; Brian C Jensen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-12-04       Impact factor: 4.733

2.  Oral Midodrine Administration During the First 24 Hours of Sepsis to Reduce the Need of Vasoactive Agents: Placebo-Controlled Feasibility Clinical Trial.

Authors:  Amos Lal; Vrinda Trivedi; Mahrukh S Rizvi; Amy Amsbaugh; Melissa K Myers; Khaled Saleh; Rahul Kashyap; Ognjen Gajic
Journal:  Crit Care Explor       Date:  2021-05-06

3.  Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).

Authors:  Matthew H Anstey; Bradley Wibrow; Tharusan Thevathasan; Brigit Roberts; Khushi Chhangani; Pauline Yeung Ng; Alexander Levine; Alan DiBiasio; Todd Sarge; Matthias Eikermann
Journal:  BMC Anesthesiol       Date:  2017-03-21       Impact factor: 2.217

4.  Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial.

Authors:  Peter Santer; Matthew H Anstey; Maria D Patrocínio; Bradley Wibrow; Bijan Teja; Denys Shay; Shahzad Shaefi; Charles S Parsons; Timothy T Houle; Matthias Eikermann
Journal:  Intensive Care Med       Date:  2020-09-03       Impact factor: 17.440

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.